The deal includes $635 million in upfront payments and as much as $100 million in potential sales.
Emergent said it plans to expand the use of the lifesaving nasal spray while maintaining the drug’s affordability. It expects to generate about $220 million in revenue from the product in 2019.
The drugmaker is looking into contracting with the government to expand access to the treatment.
Police departments and school campuses have increasingly been using the product, partially because of Adapt Pharma’s efforts to give away the drug for free or at a reduced rate.
More articles on pharmacy:
A patient paid $285 for a $40 drug: Here’s why
HHS Secretary: We have the power to eliminate rebates
Roche’s Genentech to cut 223 jobs in California
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
